Multicenter, randomized trial for protection of post ERCP pancreatitis with/without Risperidone(Tokyo P3R)

Not Applicable

• Conditions: protection of post ERCP pancreatitis

• Registration Number: JPRN-UMIN000000505
• Lead Sponsor: Faculty of Medicine, University of Tokyo

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2006-10-27
• Study Completion: 2008-12-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Not provided

Exclusion Criteria

Patients with a history of Endoscopic sphincterotomy. Patients have acute pancreatitis or acute exacerbation of chronic pancreatitis need the fasting therapy. Patients have disseminated intravascular coagulation,sepsis,acute. Patients have severe disturbance of consciousness than Japan Coma Scale1-1. Patients have severeheart disease,hepatic insufficiency,compromised renal function,endocrine disease,and gastrointestinal tract disturbance. Pregnant and breast-feeding women or women suspected of being pregnant,women are not willing to avoid pregnancy during the duration of study . Patients on Risperidone. Patients with a history of severe hypersensitivity to the Risperidone and Urinastatin. Patients have mental illness or depression who need continued medication or can not comply with the protocol. Patients with Parkinson's disease or parkinsonism. Patients receiving banned drug within 2 weeks before pre-observations. Patients with a history of enrolled in this clinical trial. Somebody who are found unfit to be patients by investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified